2. Search Result
Search Result
Results for "

Parkinson disease and dementia with Lewy bodies

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-170035
    GlcCer (d18:1/18:0)

    C18 Glucosyl(β) ceramide (d18:1/18:0); D-glucosyl-β-1,1' N-stearoyl-D-erythro-sphingosine

    		 Liposome Neurological Disease
    GlcCer (d18:1/18:0) (C18 Glucosyl(β) ceramide (d18:1/18:0)) is a glycosphingolipid. GlcCer (d18:1/18:0) is promising for research of Parkinson disease and dementia with Lewy bodies .
    GlcCer (d18:1/18:0)
  • HY-135653A
    (Rac)-EC5026

    (Rac)-BPN-19186

    		 Epoxide Hydrolase Neurological Disease
    (Rac)-EC5026 ((Rac)-BPN-19186) is a potent piperidine inhibitor of soluble epoxide hydrolase (sEH) extracted from patent WO2019156991A1, page 39, has a Ki of 0.06 nM. (Rac)-EC5026 can be used for the research of Parkinson's disease and dementia with Lewy Bodies (DLB) .
    (Rac)-EC5026
  • HY-125287
    (Rac)-Minzasolmin

    (Rac)-UCB0599; NPT200-11

    		 α-synuclein Neurological Disease
    (Rac)-Minzasolmin ((Rac)-UCB0599; NPT200-11) is a blood-brain barrier penetrated alpha-synuclein (ASYN) misfolding inhibitor. (Rac)-Minzasolmin acts on the early stage of ASYN aggregation process, by replacing the membrane-bound oligomers ASYN, allowing them to revert to the monomeric form, while preventing pathological aggregation. (Rac)-Minzasolmin effectively improves the ASYN deposition in the retina and the neuro-pathological indicators in two α-synuclein transgenic mouse models. (Rac)-Minzasolmin can be used for the studies of Parkinson's disease (PD) and dementia with Lewy bodies (DLB) .
    (Rac)-Minzasolmin
  • HY-160116
    α-Synuclein aggregate binder 1

    		Radionuclide-Drug Conjugates (RDCs) Fluorescent Dye α-synuclein Neurological Disease
    α-Synuclein aggregate binder 1 (Compound C05-05) is a specific binder for α-synuclein aggregates and can inhibit α-synuclein aggregation. α-Synuclein aggregate binder 1 can be used as a fluorescent probe (excitation wavelength 900 nm, detection wavelength 500-550 nm) for optical imaging, and can also inhibit α-synuclein fibril formation by blocking the aggregation process. α-Synuclein aggregate binder 1 can be used for positron emission tomography (PET) imaging after being labeled with 18F. α-Synuclein aggregate binder 1 can be used for visual diagnosis of brain lesions and mechanism research of neurodegenerative diseases such as Parkinson's disease and Lewy body dementia .
    α-Synuclein aggregate binder 1
  • HY-175308
    α-Synuclein inhibitor 15

    		α-synuclein Neurological Disease
    α-Synuclein inhibitor 15 (Compound 1) is an inhibitor targeting the fibrillation growth of α-synuclein (IC50=18 μM). α-Synuclein inhibitor 15 is promising for research of neurodegenerative diseases, such as Parkinson's disease (PD) and Lewy body dementia (LBD) .
    α-Synuclein inhibitor 15
  • HY-153127
    Florbenazine

    AV-133

    		 Biochemical Assay Reagents Neurological Disease
    Florbenazine (AV-133) is a diagnostic imaging agent targeting the central nervous system monoamine transporter VMAT2, and its F-18 labeled form can be used for PET scanning. The biodistribution of [18F]Florbenazine in mice shows a high striatum/cerebellum ratio (0.48), which can be used for the diagnostic research of neurodegenerative diseases (including dementia with Lewy bodies and Parkinson's disease) .
    Florbenazine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: